Dorzolamide hydrochloride and visual function in normal eyes

W. E. Sponsel, J. Harrison, W. R. Elliott, Y. Trigo, J. Kavanagh, Alon Harris

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

PURPOSE: To determine by a pilot study whether standard treatment with the topical carbonic anhydrase inhibitor dorzolamide hydrochloride influences visual function under normal breathing conditions, during carbon dioxide inhalation, or during hyperventilation, and to establish criteria for future larger-scale studies. METHODS: We enrolled 12 normal subjects into this randomized double-masked placebo-controlled crossover study. Each subject was treated with either dorzolamide 2% or placebo, three times daily, for 4 days. After a 2-week washout period, the alternative topical agent was used under identical testing conditions. On day 2 of each treatment phase, contrast sensitivities to sinusoidal gratings of 1 and 4 cycles per degree (cpd) were assessed. On day 4, mean deviation values from full-threshold 10-2 visual fields were obtained. Three sets of each visual function test were obtained before each treatment phase, and in sequence on each testing day, during normal breathing (baseline), inhalation of carbon dioxide-enriched air, and hyperventilation while intraocular pressure was monitored. RESULTS: Contrast sensitivity at 4 cpd decreased significantly (P <.01) during carbon dioxide supplementation with placebo but showed no significant change with dorzolamide. The decrease in contrast sensitivity accompanying hyperventilation was attenuated (by nearly 50% at 1 cpd) during dorzolamide treatment. Dorzolamide treatment was associated with higher perimetry mean deviation values under each treatment condition and was statistically significant (P <.05) at baseline. CONCLUSIONS: Dorzolamide appears to enhance contrast sensitivity in normal subjects during physiologic hypercapnia and hypocapnia at 4 and 1 cpd, respectively. Also, under normal breathing conditions, dorzolamide therapy increases perimetric light sensitivity.

Original languageEnglish (US)
Pages (from-to)759-766
Number of pages8
JournalAmerican Journal of Ophthalmology
Volume123
Issue number6
StatePublished - 1997
Externally publishedYes

Fingerprint

dorzolamide
Contrast Sensitivity
Hyperventilation
Carbon Dioxide
Respiration
Placebos
Inhalation
Therapeutics
Hypocapnia
Carbonic Anhydrase Inhibitors
Photophobia
Visual Field Tests
Hypercapnia
Visual Fields
Intraocular Pressure
Cross-Over Studies

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Sponsel, W. E., Harrison, J., Elliott, W. R., Trigo, Y., Kavanagh, J., & Harris, A. (1997). Dorzolamide hydrochloride and visual function in normal eyes. American Journal of Ophthalmology, 123(6), 759-766.

Dorzolamide hydrochloride and visual function in normal eyes. / Sponsel, W. E.; Harrison, J.; Elliott, W. R.; Trigo, Y.; Kavanagh, J.; Harris, Alon.

In: American Journal of Ophthalmology, Vol. 123, No. 6, 1997, p. 759-766.

Research output: Contribution to journalArticle

Sponsel, WE, Harrison, J, Elliott, WR, Trigo, Y, Kavanagh, J & Harris, A 1997, 'Dorzolamide hydrochloride and visual function in normal eyes', American Journal of Ophthalmology, vol. 123, no. 6, pp. 759-766.
Sponsel WE, Harrison J, Elliott WR, Trigo Y, Kavanagh J, Harris A. Dorzolamide hydrochloride and visual function in normal eyes. American Journal of Ophthalmology. 1997;123(6):759-766.
Sponsel, W. E. ; Harrison, J. ; Elliott, W. R. ; Trigo, Y. ; Kavanagh, J. ; Harris, Alon. / Dorzolamide hydrochloride and visual function in normal eyes. In: American Journal of Ophthalmology. 1997 ; Vol. 123, No. 6. pp. 759-766.
@article{75e3de083ffd4f58b331e2cb1d302c0d,
title = "Dorzolamide hydrochloride and visual function in normal eyes",
abstract = "PURPOSE: To determine by a pilot study whether standard treatment with the topical carbonic anhydrase inhibitor dorzolamide hydrochloride influences visual function under normal breathing conditions, during carbon dioxide inhalation, or during hyperventilation, and to establish criteria for future larger-scale studies. METHODS: We enrolled 12 normal subjects into this randomized double-masked placebo-controlled crossover study. Each subject was treated with either dorzolamide 2{\%} or placebo, three times daily, for 4 days. After a 2-week washout period, the alternative topical agent was used under identical testing conditions. On day 2 of each treatment phase, contrast sensitivities to sinusoidal gratings of 1 and 4 cycles per degree (cpd) were assessed. On day 4, mean deviation values from full-threshold 10-2 visual fields were obtained. Three sets of each visual function test were obtained before each treatment phase, and in sequence on each testing day, during normal breathing (baseline), inhalation of carbon dioxide-enriched air, and hyperventilation while intraocular pressure was monitored. RESULTS: Contrast sensitivity at 4 cpd decreased significantly (P <.01) during carbon dioxide supplementation with placebo but showed no significant change with dorzolamide. The decrease in contrast sensitivity accompanying hyperventilation was attenuated (by nearly 50{\%} at 1 cpd) during dorzolamide treatment. Dorzolamide treatment was associated with higher perimetry mean deviation values under each treatment condition and was statistically significant (P <.05) at baseline. CONCLUSIONS: Dorzolamide appears to enhance contrast sensitivity in normal subjects during physiologic hypercapnia and hypocapnia at 4 and 1 cpd, respectively. Also, under normal breathing conditions, dorzolamide therapy increases perimetric light sensitivity.",
author = "Sponsel, {W. E.} and J. Harrison and Elliott, {W. R.} and Y. Trigo and J. Kavanagh and Alon Harris",
year = "1997",
language = "English (US)",
volume = "123",
pages = "759--766",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Dorzolamide hydrochloride and visual function in normal eyes

AU - Sponsel, W. E.

AU - Harrison, J.

AU - Elliott, W. R.

AU - Trigo, Y.

AU - Kavanagh, J.

AU - Harris, Alon

PY - 1997

Y1 - 1997

N2 - PURPOSE: To determine by a pilot study whether standard treatment with the topical carbonic anhydrase inhibitor dorzolamide hydrochloride influences visual function under normal breathing conditions, during carbon dioxide inhalation, or during hyperventilation, and to establish criteria for future larger-scale studies. METHODS: We enrolled 12 normal subjects into this randomized double-masked placebo-controlled crossover study. Each subject was treated with either dorzolamide 2% or placebo, three times daily, for 4 days. After a 2-week washout period, the alternative topical agent was used under identical testing conditions. On day 2 of each treatment phase, contrast sensitivities to sinusoidal gratings of 1 and 4 cycles per degree (cpd) were assessed. On day 4, mean deviation values from full-threshold 10-2 visual fields were obtained. Three sets of each visual function test were obtained before each treatment phase, and in sequence on each testing day, during normal breathing (baseline), inhalation of carbon dioxide-enriched air, and hyperventilation while intraocular pressure was monitored. RESULTS: Contrast sensitivity at 4 cpd decreased significantly (P <.01) during carbon dioxide supplementation with placebo but showed no significant change with dorzolamide. The decrease in contrast sensitivity accompanying hyperventilation was attenuated (by nearly 50% at 1 cpd) during dorzolamide treatment. Dorzolamide treatment was associated with higher perimetry mean deviation values under each treatment condition and was statistically significant (P <.05) at baseline. CONCLUSIONS: Dorzolamide appears to enhance contrast sensitivity in normal subjects during physiologic hypercapnia and hypocapnia at 4 and 1 cpd, respectively. Also, under normal breathing conditions, dorzolamide therapy increases perimetric light sensitivity.

AB - PURPOSE: To determine by a pilot study whether standard treatment with the topical carbonic anhydrase inhibitor dorzolamide hydrochloride influences visual function under normal breathing conditions, during carbon dioxide inhalation, or during hyperventilation, and to establish criteria for future larger-scale studies. METHODS: We enrolled 12 normal subjects into this randomized double-masked placebo-controlled crossover study. Each subject was treated with either dorzolamide 2% or placebo, three times daily, for 4 days. After a 2-week washout period, the alternative topical agent was used under identical testing conditions. On day 2 of each treatment phase, contrast sensitivities to sinusoidal gratings of 1 and 4 cycles per degree (cpd) were assessed. On day 4, mean deviation values from full-threshold 10-2 visual fields were obtained. Three sets of each visual function test were obtained before each treatment phase, and in sequence on each testing day, during normal breathing (baseline), inhalation of carbon dioxide-enriched air, and hyperventilation while intraocular pressure was monitored. RESULTS: Contrast sensitivity at 4 cpd decreased significantly (P <.01) during carbon dioxide supplementation with placebo but showed no significant change with dorzolamide. The decrease in contrast sensitivity accompanying hyperventilation was attenuated (by nearly 50% at 1 cpd) during dorzolamide treatment. Dorzolamide treatment was associated with higher perimetry mean deviation values under each treatment condition and was statistically significant (P <.05) at baseline. CONCLUSIONS: Dorzolamide appears to enhance contrast sensitivity in normal subjects during physiologic hypercapnia and hypocapnia at 4 and 1 cpd, respectively. Also, under normal breathing conditions, dorzolamide therapy increases perimetric light sensitivity.

UR - http://www.scopus.com/inward/record.url?scp=0031005744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031005744&partnerID=8YFLogxK

M3 - Article

C2 - 9535619

AN - SCOPUS:0031005744

VL - 123

SP - 759

EP - 766

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 6

ER -